Table 4.
AUC of the Aβ plasma change from the trough level in the 2-week dosing interval (Intent-to-treat population; n=55).
| IVIG (n=20) | Placebo (n=7) | Placebo vs. 0.1 IVIG | Placebo vs. 0.25 IVIG | Placebo vs. 0.4 IVIG | |||
|---|---|---|---|---|---|---|---|
| 0.1 (n=6) | 0.25 (n=7) | 0.4 (n=7) | |||||
| Aβ1–40 | −13.75 [−1729.0; 307.0] (n=6) |
−32.50 [−1102.5; 451.5] (n=7) |
47.00 [−341.0; 72.5] (n=5) |
159.50 [51.5; 303.0] (n=5) |
159.75 [−124.5; 1838.5] p=0.2353 |
200.50 [−51.0; 474.5] p=0.0740 |
134.50 [4.5; 500.5] p=0.0216 |
| Aβ1–42 | 3.00 [−109.50; 74.50] (n=6) |
−33.50 [−190.55; −16.50] (n=7) |
−9.50 [−57.00; 5.00] (n=5) |
24.00 [2.00; 125.50] (n=5) |
26.50 [−45.0; 133.5] p=0.1207 |
63.00 [40.0; 178.0] p=0.0058 |
39.00 [−11.5; −135.0] p=0.0216 |
| nAbs-Aβ | 299.25 [−105.0; 987.0] (n=6) |
1256.00 [1059.0; 5160.0] (n=7) |
2172.00 [−710.5; 5516.0] (n=5) |
593.00 [−1090.5; 7747.5] (n=5) |
580.75 [−1258.0; 7316.5] p=0.4113 |
−641.50 [−2346.5; 6009.5] p=0.6261 |
−380.00 [−4923.0; 6600.0] p=1.000 |
Data are median [minimum, maximum] (patients analysed) for treatment groups; differences are assessed by Hodges-Lehmann estimates of the difference in two medians and the corresponding non-parametric 95% confidence interval (exact) as well as by Wilcoxon Rank Sum test (normal approximation, two-sided, α=0.05).